← All trials
NCT04010448
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 15, 2019
- Primary completion
- Aug 15, 2024
- Completion date
- Dec 15, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 8200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- PATHLead sponsor
- Bill and Melinda Gates FoundationCollaborator
- SK Bioscience Co., Ltd.Collaborator
- University of GhanaOverall official - principal investigator
- University of MalawiOverall official - principal investigator
- Centre for Infectious Disease Research in Zambia (CIDRZ)Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.